The eyes in diabetes and diabetes through the eyes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F07%3A%230000741" target="_blank" >RIV/00064190:_____/07:#0000741 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.diabres.2007.09.023" target="_blank" >http://dx.doi.org/10.1016/j.diabres.2007.09.023</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.diabres.2007.09.023" target="_blank" >10.1016/j.diabres.2007.09.023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The eyes in diabetes and diabetes through the eyes

Popis výsledku v původním jazyce

Diabetic retinopathy (DR) is the most common of the microvascular complications of diabetes. Left unchecked and untreated, it could progresses from a non-proliferative phase to a proliferative, sight-threatening phase. Macular edema which also threatenssight can appear at any stage. The pathophysiological mechanisms underlying its appearance and progression include the accumulation of plyols, advanced glycation endproducts (AGE) reactive oxygen species, release of local growth factors and activation ofprotein kinase C, all of which lead to structural and functional changes in the retina which can progress to threaten sight. Tight glucose and blood pressure control can prevent the appearance and progression of retinopathy. Novel PKC inhibitors, inhibitors of growth factors, blockers of the renin-angiotensin system (RAS) as well as statins can slow the progression of DR and protect sight.

Název v anglickém jazyce

The eyes in diabetes and diabetes through the eyes

Popis výsledku anglicky

Diabetic retinopathy (DR) is the most common of the microvascular complications of diabetes. Left unchecked and untreated, it could progresses from a non-proliferative phase to a proliferative, sight-threatening phase. Macular edema which also threatenssight can appear at any stage. The pathophysiological mechanisms underlying its appearance and progression include the accumulation of plyols, advanced glycation endproducts (AGE) reactive oxygen species, release of local growth factors and activation ofprotein kinase C, all of which lead to structural and functional changes in the retina which can progress to threaten sight. Tight glucose and blood pressure control can prevent the appearance and progression of retinopathy. Novel PKC inhibitors, inhibitors of growth factors, blockers of the renin-angiotensin system (RAS) as well as statins can slow the progression of DR and protect sight.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

DIABETES RESEARCH AND CLINICAL PRACTICE

ISSN

0168-8227

e-ISSN

—

Svazek periodika

77

Číslo periodika v rámci svazku

Supl. 1

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

7

Strana od-do

"S51-S58"

Kód UT WoS článku

000252392800008

EID výsledku v databázi Scopus

—